# Twist Bioscience Corporation (TWST) Stock Analysis: Unveiling a 46% Upside Potential for Investors

- Link: https://www.directorstalkinterviews.com/twist-bioscience-corporation-twst-stock-analysis-unveiling-a-46-upside-potential-for-investors/4121213653
- Published: 2025-08-26T10:24:06+01:00
- Author: Madison Wilson

Twist Bioscience Corporation (NASDAQ: TWST) has captured the attention of investors
with its innovative approach to synthetic DNA-based products. Operating within the
healthcare sector, specifically in the diagnostics and research industry, Twist 
Bioscience is headquartered in South San Francisco, California. Despite its relatively
nascent presence in the market, the company has carved out a niche with its cutting-
edge solutions in gene synthesis and synthetic biology, serving a diverse array 
of sectors from therapeutics to agriculture and data storage.

Currently, Twist Bioscience has a market capitalization of $1.65 billion and trades
at $27.39 per share. The stock’s 52-week range of $25.00 to $54.07 demonstrates 
significant volatility and a wide trading band, which might intrigue investors looking
for both risk and potential reward. The recent price change reflects a slight decline
of 0.04%, but the broader narrative is more compelling when considering analyst 
ratings and target prices.

Analysts have shown considerable optimism towards Twist Bioscience, with seven buy
ratings out of nine total analyst recommendations. The average target price is set
at $40.00, suggesting a potential upside of 46.04% from its current trading price—
a figure that should certainly pique the interest of growth-focused investors. The
bullish sentiment is further reflected in the target price range of $25.00 to $50.00,
indicating room for substantial appreciation as the company continues to innovate
and expand its product offerings.

However, investors should also consider the company’s financial and performance 
metrics. Twist Bioscience is currently not profitable, evidenced by a negative earnings
per share (EPS) of -1.44 and a return on equity (ROE) of -17.58%. The lack of profitability
is typical of young, high-growth companies investing heavily in research and development.
The revenue growth rate of 17.90% is promising, showcasing the company’s ability
to expand its top line despite the current net income challenges. Free cash flow
stands at -$24,547,124, underscoring the capital intensity of its operations and
the need for continued investment.

From a technical perspective, Twist Bioscience’s 50-day and 200-day moving averages
stand at $33.28 and $39.65, respectively. The current trading price below these 
averages might be perceived as a bearish indicator in the short term. However, the
relative strength index (RSI) of 55.72 suggests that the stock is neither overbought
nor oversold, offering a neutral stance for potential investors.

While the company does not offer dividends, which is typical for firms reinvesting
earnings into growth, its strategic partnerships and product innovations, such as
synthetic SARS-CoV-2 RNA reference sequences and precision DNA libraries, position
it well for future growth. The collaboration with bitBiome Inc. further enhances
its capabilities in DNA data storage, a burgeoning field with vast potential.

Investors considering a stake in Twist Bioscience should weigh the inherent risks
of investing in a high-growth, pre-profitability company against the significant
upside potential implied by analyst targets. As the demand for synthetic biology
solutions continues to rise across various industries, Twist Bioscience is well-
positioned to capitalize on these trends, potentially rewarding investors who are
willing to navigate the volatility and invest for the long haul.

Share on: